Holen Sie sich die Stockscreener-App
48.39
1.51%
-0.7249
Schlusskurs vom Vortag:
$49.11
Offen:
$48.7238
24-Stunden-Volumen:
14.44M
Relative Volume:
0.83
Marktkapitalisierung:
$71.92B
Einnahmen:
$20.62B
Nettoeinkommen (Verlust:
$3.56B
KGV:
20.29
EPS:
2.3847
Netto-Cashflow:
$3.48B
1W Leistung:
-16.28%
1M Leistung:
-15.36%
6M Leistung:
-52.38%
1J Leistung:
-53.71%
1-Tages-Spanne:
$48.18
$49.30
1-Wochen-Bereich:
$48.18
$58.13
52-Wochen-Spanne:
$48.18
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Firmenname
Boston Scientific Corp
Sektor
Branche
Telefon
508-683-4000
Adresse
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX vs ABT, SYK, MDT, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
48.39 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
ABT
Abbott Laboratories
|
85.69 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.01 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
74.65 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
EW
Edwards Lifesciences Corp
|
86.76 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-10-03 | Herabstufung | Erste Group | Buy → Hold |
| 2025-09-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-16 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-16 | Hochstufung | Needham | Hold → Buy |
| 2025-01-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Herabstufung | Needham | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-06-30 | Eingeleitet | CL King | Buy |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-20 | Fortgesetzt | Citigroup | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-05-27 | Hochstufung | Needham | Hold → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Buy |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-05-26 | Herabstufung | Needham | Buy → Hold |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-17 | Eingeleitet | Truist | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-04-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Buy |
| 2019-12-30 | Bestätigt | Cowen | Outperform |
| 2019-12-19 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-09-05 | Fortgesetzt | JP Morgan | Overweight |
| 2019-09-03 | Fortgesetzt | Barclays | Overweight |
| 2019-05-13 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-10-02 | Bestätigt | Morgan Stanley | Overweight |
| 2018-09-07 | Bestätigt | Needham | Strong Buy |
| 2018-09-04 | Hochstufung | Jefferies | Hold → Buy |
| 2018-07-06 | Bestätigt | Needham | Strong Buy |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-04-26 | Bestätigt | Needham | Strong Buy |
Alle ansehen
Boston Scientific Corp Aktie (BSX) Neueste Nachrichten
BSX Downgraded by Wolfe Research -- Rating Changed to Peer Perfo - GuruFocus
Wolfe Research cuts Boston Scientific rating as key growth drivers falter - Investing.com Nigeria
Wolfe Research downgrades Boston Scientific stock rating on growth concerns - Investing.com
Boston Scientific’s $1.5B bet signals heart valve market battle - Modern Healthcare News
Barclays Remains a Buy on Boston Scientific (BSX) - The Globe and Mail
Why Boston Scientific Stock Was Sliding This Week - The Motley Fool
Our Boston Scientific Pick Has Suffered. We’re Pulling the Recommendation. - Barron's
Assessing Boston Scientific (BSX) Valuation After Strong SEISMIQ 4CE Trial Results - simplywall.st
Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
BSX Maintained by Leerink Partners -- Price Target Lowered to $7 - GuruFocus
Press Release: Pablo José Hernández Rivera Visits Boston Scientific in Dorado to Highlight Potential of Medical Manufacturing in Puerto Rico - Quiver Quantitative
This Boston Scientific Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Thursday - Benzinga
Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown - Investing.com
RBC Capital reiterates Boston Scientific stock rating on Watchman outlook - Investing.com
Citigroup Adjusts Boston Scientific Price Target to $70 From $87, Maintains Buy Rating - marketscreener.com
Bernstein Adjusts Boston Scientific Price Target to $76 From $97, Maintains Outperform Rating - marketscreener.com
Leerink cuts Boston Scientific stock price target on Watchman outlook - Investing.com
Leerink Partners Adjusts PT on Boston Scientific to $74 From $87, Maintains Outperform Rating - marketscreener.com
Wells Fargo Downgrades Boston Scientific to Equalweight From Overweight, Adjusts PT to $55 From $75 - marketscreener.com
Goldman Sachs Adjusts Price Target on Boston Scientific to $71 From $81, Maintains Buy Rating - Moomoo
Barclays Adjusts Price Target on Boston Scientific to $89 From $96, Maintains Overweight Rating - marketscreener.com
Time To Buy The Dip In Boston Scientific Stock? - Trefis
Boston Scientific Stock Falls 12% In A Single Day, Time To Buy The Stock? - Trefis
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance - The Motley Fool
Boston Scientific Corp (BSX) Stock Down 12.5% -- Now Undervalued? GF Score: 83/100 - GuruFocus
Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial - Insider Monkey
Watchman Woes: Boston Scientific Shares Plunge on Weak Demand - Medical Device and Diagnostic industry
Boston Scientific Is the Worst Performing S&P 500 Stock. Here’s Why. - Barron's
Boston Scientific Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention - The Motley Fool
Boston Scientific Is Betting $1.5 Billion on a Massive Market -- and Wall Street Is Paying Attention - The Motley Fool
Boston Scientific (BSX) Plunges 10.3% to $51.69 - AlphaStreet
Boston Scientific hits two-year low after flagging weaker demand for heart device - Reuters
Boston Scientific shares fall 10% on Watchman weakness, competitive pressures - Investing.com
Boston Scientific slides after flagging slowdown in Watchman heart device usage - marketscreener.com
Boston Scientific slides after flagging slowdown in Watchmen heart device usage - AOL.com
Boston Scientific (BSX) Shares Drop 10% Amid Demand Slowdown for WATCHMAN Implant - GuruFocus
Stifel Adjusts Price Target on Boston Scientific to $75 From $85, Maintains Buy Rating - marketscreener.com
Boston Scientific (BSX) slides after management cuts 2026 growth outlook - Quiver Quantitative
Boston Scientific (BSX) Plunges 10% Following Bernstein Conference Guidance Revision - Blockonomi
Here’s Why Boston Scientific Stock (BSX) Is Crashing Today - TipRanks
Boston Scientific falls on Watchman headwinds (BSX:NYSE) - Seeking Alpha
Why is Boston Scientific stock plunging today? - Investing.com
Why is Boston Scientific stock plunging today? By Investing.com - Investing.com Canada
Boston Scientific Down Over 10%, On Track for Lowest Close Since November 2023 -- Data Talk - Moomoo
Cramer’s Stop Trading: Boston Scientific - CNBC
Boston Scientific stock hits 52-week low at $52.29 By Investing.com - Investing.com Nigeria
Boston Scientific stock hits 52-week low at $52.29 - Investing.com
Boston Scientific stock tumbles 6% after guidance cut By Investing.com - Investing.com Australia
Goldman Sachs Adjusts Price Target on Boston Scientific to $81 From $84, Maintains Buy Rating - Moomoo
Boston Scientific makes corporate venture move with MiRus stake - Global Venturing
Finanzdaten der Boston Scientific Corp-Aktie (BSX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
0.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):